ストックスクリーナーアプリを入手
1.84
0.00%
0.00
アフターアワーズ：
1.84
前日終値:
$1.84
開ける：
$1.85
24時間の取引高:
9.41M
Relative Volume:
1.21
時価総額：
$555.51M
収益：
$188.87M
当期純損益:
$-400.38M
株価収益率:
-1.2267
EPS:
-1.5
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
+7.29%
1か月 パフォーマンス:
-8.46%
6か月 パフォーマンス:
+52.07%
1年 パフォーマンス:
+35.29%
1日の値動き範囲:
$1.76
$1.92
1週間の範囲:
$1.6925
$1.92
52週間の値動き範囲:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.84 | 555.51M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Pacific Biosciences of California Inc (PACB) Q4 2025 Earnings Ca - GuruFocus
Pacific Biosciences of California Q4 Earnings Call Highlights - MarketBeat
Pacific Biosciences of California (PACB) reports Q4 loss, beats revenue estimates - MSN
Earnings call transcript: Pacific Biosciences beats Q4 2025 forecasts By Investing.com - Investing.com Canada
PACB: Record consumable growth and SparkNex launch set stage for 8% revenue growth in 2026 - TradingView
PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025 - Finviz
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Announces Earnings Results - MarketBeat
Pacific Biosciences: Q4 Earnings Snapshot - kens5.com
PacBio (PACB) Surpasses Q4 Revenue Expectations Amid Strategic E - GuruFocus
PacBio (PACB) Q4 2025 Earnings Call Transcript - The Globe and Mail
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
PacBio (NASDAQ: PACB) lifts 2025 revenue but posts large restructuring-driven loss - Stock Titan
Pacific Biosciences of California joins iHope to expand genomic sequencing access - Traders Union
PacBio tech joins iHope to help rare disease patients get answers - Stock Titan
Valuation Update: Is Freedom Holding Corp in a bullish channelEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Pacific Biosciences: Fourth Quarter Earnings Overview - Bitget
How strong is Pacific Biosciences of California Inc. stock revenue growth2025 Stock Rankings & Risk Controlled Stock Alerts - mfd.ru
PacBio Earnings: What To Look For From PACB - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt - 富途牛牛
How The Narrative Around Pacific Biosciences Of California (PACB) Is Shifting As Assumptions Evolve - Yahoo Finance
Buyback Watch: Will BIIB benefit from sector rotationPortfolio Value Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Pacific Biosciences of California (PACB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Risk Recap: Can Pacific Biosciences of California Inc. reach all time highs this yearWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Pacific Biosciences showcases automation options at SLAS2026 - Traders Union
Pacific Biosciences Announces Interim Leadership Role Realignment - TipRanks
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Nigeria
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 7.7%Here's Why - MarketBeat
Pacific Biosciences Sees Strategic Maneuvers Amid Financial Woes - StocksToTrade
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Pacific Biosciences Strengthens Balance Sheet via Asset Sale - TipRanks
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
PacBio Completes Sale of Short-Read Sequencing Assets to Illumina for $48.1 Million - Quiver Quantitative
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Stock Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market - sharewise.com
Pacific Biosciences of California (PACB) Stock Analysis: Navigating Growth Potential Amidst Market Challenges - DirectorsTalk Interviews
Pacific Biosciences of California unveils HiFiSequencing turning points at FOG2026 - Traders Union
Analyst Downgrade: Will Pacific Biosciences of California Inc outperform during market ralliesPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation (NASDAQ:PACB) - Seeking Alpha
PacBio To Report Q4 And FY25 Financial Results In Feb - Nasdaq
Pacific Biosciences showcases HiFi sequencing at FOG2026 in London - Traders Union
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Sahm
Pacific Biosciences stock shows signs of recovery, Canaccord maintains Buy By Investing.com - Investing.com Canada
How The New Price Target Is Reframing The Story For Pacific Biosciences (PACB) - Yahoo Finance
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week HighTime to Buy? - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 7.9%Still a Buy? - MarketBeat
Here's why you should add PacBio stock to your portfolio - MSN
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
0.31%
大文字化:
|
ボリューム (24 時間):